Innate Pharma Reports Full Year 2025 Financial Results and Business Update

AI Briefing

• – Innate Pharma reports strong execution across its portfolio, with FDA clearance in hand for lacutamab, and plans for confirmatory Phase 3 initiation.
• – Financial results to be attached to the press release, including consolidated financial statements.
• – No specific details on revenue or earnings reported.